首页> 外文期刊>Neuropharmacology >The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB 1)
【24h】

The endocannabinoid N-arachidonoyldopamine (NADA) exerts neuroprotective effects after excitotoxic neuronal damage via cannabinoid receptor 1 (CB 1)

机译:内源性大麻素N-花生四烯酸多巴胺(NADA)在通过大麻素受体1(CB 1)引起兴奋性神经元损伤后发挥神经保护作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Endocannabinoids exert numerous effects in the CNS under physiological and pathological conditions. The aim of the present study was to examine whether the endocannabinoid N-arachidonoyldopamine (NADA) may protect neurons in excitotoxically lesioned organotypic hippocampal slice cultures (OHSC). OHSC were excitotoxically lesioned by application of N-methyl-d-aspartate (NMDA, 50 μM) for 4 h and subsequently treated with different NADA concentrations (0.1 pM-50 μM) alone or in combination with cannabinoid receptor antagonists. NADA protected dentate gyrus granule cells and caused a slight reduction in the number of microglial cells. The number of degenerated neurons significantly decreased between 100 pM and 10 μM NADA (p 0.05). To identify the responsive receptor type of NADA mediated neuroprotection, we applied the cannabinoid (CB) receptor 1 (CB 1) inverse agonist/antagonist AM251, CB 2 inverse agonist/antagonist AM630, abnormal-cannabidiol (abn-CBD)-sensitive receptor antagonist O-1918, transient receptor potential channel V1 (TRPV1) antagonist 6-iodonordihydrocapsaicin and A1 (TRPA1) antagonist HC-030031. Neuroprotective properties of low (1 nM) but not high (10 μM) NADA concentrations were solely blocked by AM251 and were absent in CB1-/- mice. AM630, O-1918, 6-iodonordihydrocapsaicin and HC-030031 showed no effects at all NADA concentrations applied. Our findings demonstrate that NADA protects dentate gyrus granule cells by acting via CB 1. NADA reduced the number of microglial cells at distinct concentrations. TRPV1 and TRPA1 were not involved in NADA mediated neuroprotection. Thus, our data implicate that NADA mediated activation of neuronal CB 1 may serve as a novel pharmacological target to mitigate symptoms of neuronal damage.
机译:内源性大麻素在生理和病理条件下可在中枢神经系统中发挥多种作用。本研究的目的是检查内源性大麻素N-花生四烯酸多巴胺(NADA)是否可以保护兴奋性毒性病变器官型海马切片培养物(OHSC)中的神经元。通过应用N-甲基-d-天门冬氨酸(NMDA,50μM)对OHSC进行兴奋性毒性损伤4小时,然后单独或与大麻素受体拮抗剂联合用不同的NADA浓度(0.1 pM-50μM)处理。 NADA保护齿状回颗粒细胞,并导致小胶质细胞数量略有减少。在100 pM和10μMNADA之间,退化神经元的数量显着减少(p <0.05)。为了识别NADA介导的神经保护反应性受体类型,我们应用了大麻素(CB)受体1(CB 1)反向激动剂/拮抗剂AM251,CB 2反向激动剂/拮抗剂AM630,对大麻二酚(abn-CBD)敏感的受体拮抗剂O-1918,瞬态受体电位通道V1(TRPV1)拮抗剂6-碘二氢辣椒素和A1(TRPA1)拮抗剂HC-030031。低(1 nM)但不高(10μM)NADA的神经保护特性仅被AM251阻断,而在CB1-/-小鼠中则不存在。 AM630,O-1918、6-碘基二氢辣椒素和HC-030031在所有施加的NADA浓度下均无作用。我们的发现表明NADA通过CB 1来保护齿状回颗粒细胞。NADA减少了不同浓度的小胶质细胞的数量。 TRPV1和TRPA1不参与NADA介导的神经保护作用。因此,我们的数据暗示NADA介导的神经元CB 1的激活可能作为减轻神经元损害症状的新型药理靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号